Journal of Pharmacovigilance

Frequency of adverse reactions caused by first line anti-tuberculosis drugs in a Moroccan cohort, Rabat- Sale-Kenitra region

10^th Pharmacovigilance Congress

September 20-21, 2017 Charlotte, USA

M El hamdouni, S Ahid, J Benamor, M Hassar, JE Bourkadi and Y Cherrah

University Mohammed V, Rabat, Morocco
My Youssef hospital, Rabat, Morocco

Scientific Tracks Abstracts: J Pharmacovigil

Abstract:

Background: The aim of this study is to evaluate the frequency of adverse drug reactions (ADRs) caused by first line anti-tuberculosis (anti-TB) drugs administered for treatment of tuberculosis (TB) among hospitalized and non-hospitalized patients in Morocco. Materials & Methods: multi-centric cohort study, from 01-01-2014 to 31-12-2015, the collection of data is based on clinical records of patients with active TB, hospitalized or not and who received first line anti-TB drugs. The study is carried out at all hospitals, all diagnostic of TB & respiratory diseases centers and all health centers where the TB is treated, the total is 19 centers situated in Rabat- Salé-Kénitra region in Morocco. ADRs are evaluated from the beginning of TB treatment until its end by a specialist clinician. The drug imputability is studied for each ADR according to the WHOâ??s method. Results: Of a total of 2532 patients treated for active TB, the average age is 37.32±16.39 years, the percentage of male gender is 70.42%, 10.03% of patients produced ADRs, which represents 445 cases in total. 7.38% of ADRs are gastrointestinal (vomiting, epigastric pain, anorexia, nausea, constipation, abdominal pain , diarrhoea), 3.67% are cutaneous (pruritus, erythema, urticaria, acne, toxiderma, rash), 1.97% are hepatic (transaminases elevation, cytolysis, jaundice, cholestasis), 1.14% are articular (arthralgea, articular pain, inferior members pain),1.06% are immunoallergic (dyspnea, edema of inferior members, anemia, thrombophlebitis) 0.67 % are neuropsychiatric (insomnia, agitation, polyneuropathy, polyneuritis, paresthesia), 0.08 % are ocular (loss of visual acuity), and 1.58 % are other ADRs such as asthenia, fever, vertigo and headache. Conclusion: ADRs caused by anti-TB drugs are frequents among patients with active TB. These ADRs must be followed up by a closer monitoring during anti-TB treatment period.

Biography :

M El hamdouni has done his PhD from the Biochemistry Department of University Mohammed V. She did his Post-doctoral work at University of California at Berkeley and went at Johns Hopkins University School of Medicine as Visiting Scientist. Presently, She is Senior Research Officer and Associate Professor of Biochemistry at OIST, Vidyasagar University.